
Agios Pharmaceuticals rose 4.2% from $26.49 to $27.60, ahead of the S&P 500's +3.2%. Its worst day was Apr 20 (−23.0%), and its low came Apr 27 at $24.43.
Nov 24, 2025 – Nov 20, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Agios Pharmaceuticals shares rose 18.6%, while the S&P 500 rose 0.4%.
+18.6%, the year's best day, on 6M shares, the year's heaviest volume · S&P 500 +0.4%
Story events cover the past 12 months · Times ET
EPS of $-1.86 beat the $-1.96 estimate on $20.0M revenue (est. $11.4M).
+1.3% · S&P 500 −1.5%
Agios Pharmaceuticals shares rose 14.3%, while the S&P 500 rose 2.9%.
+14.3% · S&P 500 +2.9%
Agios Pharmaceuticals shares fell 23.0%, while the S&P 500 fell 0.2%.
−23.0%, the year's worst day · S&P 500 −0.2%
EPS of $-1.69 beat the $-1.79 estimate on $20.7M revenue (est. $13.8M).
+13.1% · S&P 500 0.0%
Agios Pharmaceuticals closed at its highest level of the year, 66.1% above where the year started.
+17.7% · S&P 500 −0.5%
EPS of $-1.69 beat the $-1.71 estimate on $44.7M revenue (est. $25.6M).
−6.5% · S&P 500 +1.7%
Agios Pharmaceuticals shares rose 11.4%, while the S&P 500 rose 0.4%.
+11.4% · S&P 500 +0.4%
EPS of $-1.09 beat the $-1.25 estimate on $55.4M revenue (est. $50.1M).
−9.9% · S&P 500 −4.4%
Where it ended: a close of $27.60 on Nov 20, 2026. Up next: Q4 2026 earnings on Feb 11, 2027 (EPS est. $-1.09, revenue est. $61.8M).
Nothing in the past 12 months.
All AGIO dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for AGIO and SPY from Benzinga historical bars. Not investment advice.